Key Positives From The 2Q Results
A large impairment widened losses, but contracted revenue not yet recognized from M3 (Mission 3), M4 (Mission 4) and other missions totals approx. JPY 50.7B (company disclosure). That provides roughly five years of revenue visibility. The ULTRA lander for M3 completed its Preliminary Design Review (PDR) incorporating the engine change, clearing a major development milestone. The US subsidiary also qualified to bid directly to NASA as a prime contractor. Revenue opportunities are therefore broadening from mainly domestic subsidies toward US government demand.
- Contract Backlog: Total contract value is JPY 18.7B for M3 and JPY 32.4B for M4. Unrecognized amounts of JPY 15.0B (M3) and JPY 32.3B (M4) remain, which should support a steady build-up in project revenue.
- ULTRA Milestone: ULTRA completed a system-wide PDR incorporating the engine change. The company signed MOUs with Nammo (engines) and ArianeGroup (thrusters) to secure ongoing supply, aiming for stable quality and lower costs.
- CLPS 2 Selection: ispace-U.S. was selected as one of eight contractors for NASA's "CLPS 2" (combined contract ceiling of USD 10B over 10 years). Its role shifts from subcontractor under the original CLPS to prime contractor able to bid directly.
- Lower Cost Base: Development-related costs (COGS excl. impairment + R&D) were JPY 3,064M (-25.1% YoY). SG&A fell 19.8% YoY. The cost structure is changing as the company moves from the R&D stage to commercialization.
- Subsidy Inflows: The company received approx. JPY 1.1B in subsidies in 1H. These are accumulating as advances received ahead of P&L recognition. Project revenue including subsidies (company estimate) was JPY 1,675M.
Key Concerns From The 2Q Results
The main driver was the approx. JPY 3.7B impairment (company disclosure) booked in 1Q for the lander model integration and engine change. Net assets shrank to JPY 5,731M (-62.2% vs. prior FY-end). 1H FCF was JPY -8,518M, and the company swung from net cash to net debt. Capital policy around the FY-end financial covenants (positive net assets and cash and deposits of at least JPY 3B) is now the key focus.
- Thin Equity Buffer: The equity ratio fell to 13.9% (-17.7pt vs. prior FY-end). The plan assumes a 2H net loss of approx. JPY 2.5B, so headroom on net assets is limited even if full-year guidance is met.
- Covenant Exposure: Borrowings subject to financial covenants total JPY 28,488M, about 92% of interest-bearing debt (report estimate). All require positive net assets and cash and deposits of at least JPY 3B at FY-end.
- M3 Launch Delay: The M3 launch is expected to slip from 2027, as agreed with the SBIR secretariat, to 2028. METI approval is still under discussion. Altitude recognition during landing also remains "not established."
- Non-Operating Drag: An FX loss of JPY 674M and interest expense of JPY 974M weighed on non-operating expenses. The 2Q standalone FX result was JPY -1,205M, a swing factor for achieving full-year guidance.
- Going-Concern Disclosure: The "material events, etc. regarding the going-concern assumption" disclosure remains in place. The company has concluded that no material uncertainty exists, citing countermeasures already under way.
Focus Areas / Items To Monitor Going Forward
- 2H Revenue Ramp: Approx. JPY 2.7B of revenue must be booked in 2H. Achieving full-year guidance depends on revenue ramping up with full-scale M4 development and the MAGPIE contract (signed in September).
- Covenant Compliance: Watch whether FY-end financial covenants are maintained and whether JPY 5,700M in subsidies (plan) is booked as non-operating income. Whether, and when, a capital policy to protect net assets is put in place is key.
- Mid-Term Growth Drivers: Watch for formal approval of the revised M3 launch timing, and for bidding and order wins on initial CLPS 2 task orders. These will determine how reliable mid-term revenue growth is.
- Outlook for METI approval of the M3 launch shift to 2028, and the impact on the SBIR subsidy receipt schedule
- Capital-raising measures to stay within FY-end financial covenants, and the funding plan including refinancing
- Bidding strategy for CLPS 2 task orders, and the expected order size and timing for the US version of ULTRA
- Specific additional measures to address altitude recognition, and the verification plan through CDR
- Visibility on 2H revenue and subsidy recognition, and the FX assumptions in full-year guidance
- Post-impairment development cost run-rate, and per-lander cost reduction targets in the mass-production phase
Key Financial Highlights
| Item | Value | YoY |
|---|---|---|
| Project Revenue | JPY 1,675M | - (company estimate) |
| Revenue | JPY 569M | -74.1% |
| Cost of Goods Sold | JPY 5,776M | +218.9% |
| └ Cost of Goods Sold (excl. impairment) | JPY 2,001M | +10.5% |
| Gross Profit | JPY -5,207M | - (prior year: JPY 382M) |
| SG&A | JPY 3,646M | -19.8% |
| └ R&D Expenses | JPY 1,063M | -53.3% |
| Total Development-Related Costs | JPY 3,064M | -25.1% |
| Operating Income | JPY -8,853M | Loss widened (prior year: JPY -4,162M) |
| └ FX Loss (Non-Operating) | JPY 674M | Prior year: FX gain of JPY 505M |
| └ Interest Expense (Non-Operating) | JPY 974M | +14.4% |
| Recurring Profit | JPY -10,445M | Loss widened (prior year: JPY -4,459M) |
| Net Income | JPY -10,451M | Loss widened (prior year: JPY -4,463M) |
| EPS | JPY -71.44 | Prior year: JPY -42.17 |
- Gross Loss Driver: The gross loss mainly reflects the approx. JPY 3.7B impairment (company disclosure) booked in COGS in 1Q. Even excluding the impairment, COGS exceeds revenue because subsidies are booked as non-operating income under the accounting treatment.
- 2Q Standalone Improvement: 2Q standalone (three months) revenue was JPY 400M, up 138.1% from JPY 168M in 1Q. The operating loss narrowed to JPY -2,456M from JPY -6,397M in 1Q.
- FX Hit At Recurring Level: The 2Q standalone FX result of JPY -1,205M weighed heavily, leaving a 2Q standalone recurring loss of JPY -4,110M.
Performance By Business Segment
The company reports a single segment, Lunar Development. Revenue declined as M2 and former M5 revenue ran its course. Meanwhile, the Japanese entity's COGS grew as M3 moved into the commercialization phase, and M4 revenue recognition began.
Segment Performance Table
| Segment | Revenue | YoY | Operating Income | YoY | Margin |
|---|---|---|---|---|---|
| Lunar Development Business (Company-Wide) | JPY 569M | -74.1% | JPY -8,853M | Loss widened | - |
- Mission 3 (Japan Entity): The main contributor to 1H revenue. The Japanese entity's COGS was JPY 1,147M (prior year: JPY 48M), reflecting the ongoing reclassification of costs from R&D to COGS.
- Mission 4 / MAGPIE (Europe): Development of the structural model has begun, and payload service revenue recognition has started. MAGPIE Phase 2 (approx. JPY 11.7B) was signed in September, with full-scale recognition expected in 2H.
- Mission 2.5 / US: Signed a launch agreement with Argo Space for a lunar orbiting satellite. Acquisition of property, plant and equipment of JPY 714M was recorded for development of the "Alpine" relay satellite.
- Mission 2 / Former Mission 5 (CP-12): Revenue booked in the prior-year period has run its course. This was the main driver of the 74.1% decline in revenue.
- US Entity: With missions completed, COGS was JPY 719M (-59.2% YoY). US-sourced revenue faces a gap until CLPS 2 task orders are won.
Progress Rate Versus Full-Year Guidance
Revenue progress was 17.2%, below the 66.3% achieved in the prior-year period against full-year actuals (report estimate). The company, however, expects revenue to be 2H-weighted, in line with full-scale M4 development and the MAGPIE contract. 1H absorbed 80.4% of the full-year net loss plan. Subsidies from SBIR and the Space Strategy Fund (plan: JPY 5,700M) are scheduled to be booked in a lump sum as non-operating income in 4Q. 2H subsidy recognition and FX trends will therefore determine whether guidance is met.
| Item | Value (2Q Cumulative) | Full-Year Forecast | Progress |
|---|---|---|---|
| Project Revenue | JPY 1,675M | JPY 9,000M | 18.6% |
| Revenue | JPY 569M | JPY 3,300M | 17.2% |
| SG&A | JPY 3,646M | JPY 11,700M | 31.2% |
| Operating Income | JPY -8,853M | JPY -17,700M | 50.0% |
| Recurring Profit | JPY -10,445M | JPY -13,000M | 80.3% |
| Net Income | JPY -10,451M | JPY -13,000M | 80.4% |
*Progress for operating income, recurring profit and net income represents the share of the planned loss absorbed (report estimate). Progress for project revenue and SG&A is per company disclosure.
Changes To Guidance
Full-year guidance announced on May 28, 2026 is maintained, with no revision. 2H assumes approx. JPY 2.7B in revenue and JPY 5,700M in subsidies. M4 progress and FX are the key swing factors.
Commentary On Shareholder Returns
The annual dividend forecast is JPY 0.00, maintaining a no-dividend policy, with no revision. There was no mention of share buybacks.
Financial Position
The impairment and operating losses reduced net assets to JPY 5,731M and the equity ratio to 13.9%. The company swung from net cash at the prior FY-end to net debt. Cash and deposits of JPY 22.5B secure near-term liquidity. Strengthening capital in light of the financial covenants, however, remains a challenge.
- Key Figures
- Leverage Metrics
| Item | Value | Additional Information |
|---|---|---|
| Cash and Cash Equivalents | JPY 22,585M | -23.9% vs. prior FY-end |
| Shareholders' Equity | JPY 5,622M | -62.7% vs. prior FY-end |
| Interest-Bearing Debt | JPY 30,888M | +4.9% vs. prior FY-end |
| └ Short-Term Borrowings | JPY 3,901M | +26.3% vs. prior FY-end |
| └ Long-Term Borrowings | JPY 26,987M | +2.4% vs. prior FY-end; includes JPY 3B from Shizuoka Bank |
| Net Debt | JPY 8,303M | Prior FY-end: net cash of JPY 247M; report estimate |
| Total Advance Payments | JPY 9,075M | Short- and long-term combined; -4.5% vs. prior FY-end |
| Advances Received + Contract Liabilities | JPY 2,259M | +199.6% vs. prior FY-end; includes approx. JPY 1.1B in subsidies |
| Operating CF / FCF | JPY -7,875M / JPY -8,518M | Prior-year period: JPY -6,647M / JPY -7,473M |
| EBITDA | JPY -8,653M | Operating income + depreciation of JPY 200M; report estimate |
| Metric | Value | Notes |
|---|---|---|
| Debt/Equity | 5.49x | Prior FY-end: 1.95x; report estimate |
| Equity Ratio | 13.9% | Prior FY-end: 31.6%; company disclosure |
Disclosures Released Alongside The Earnings Announcement
- 2026/11/13The ULTRA lander for M3 completed its PDR incorporating the engine change. The program now moves to the next phase toward CDR and flight model manufacturing
- 2026/11/13An FX loss was booked in non-operating expenses. The interim FX loss of JPY 674M contributed to the wider recurring loss
- 2026/11/13Earnings presentation released, covering the CLPS 2 selection, the KDDI partnership and the project revenue outlook including subsidies
Major Announcements During The Quarter
- 2026/09/02ispace EUROPE and ESA held a signing ceremony for "MAGPIE," Europe's first lunar polar ice exploration rover mission. It is a core pillar of M4 project revenue (approx. JPY 11.7B)
- 2026/09/09Borrowed JPY 3B from Shizuoka Bank (3-year bullet repayment, unsecured and unguaranteed, with financial covenants)
- 2026/09/17Signed a launch agreement with Argo Space for M2.5. The plan is to deploy a lunar orbiting relay communications satellite as early as 2027
- 2026/11/09ispace-U.S. was selected as one of eight contractors for NASA's "CLPS 2." It can now bid directly on individual task orders as a prime contractor
- 2026/11/12Signed an MOU with Nammo to strengthen the propulsion supply chain and cooperate on procurement. This establishes an ongoing supply framework for ULTRA's main engine
Large-Shareholding Filings / Material Proposals Over The Past Year
- Toru Akaura: 7.0%→6.3% (2026/04/24) - Held as a stable shareholder, plus pure investment via Incubate Fund No. 3 Investment Limited Partnership. Reason for filing: change in material contracts such as collateral agreements
- Heights Capital Management, Inc.: 9.0%→7.1% (2026/02/27) - Pure investment (discretionary investment agreement). Holding ratio declined by 1% or more
- Takeshi Hakamada: 11.3%→8.2% (2026/02/25) - Held as a stable shareholder in his capacity as founder and Representative Director. Reason for filing: change in material contracts such as collateral agreements
- Heights Capital Management, Inc.: 9.0%→9.0% (2026/02/25) - Pure investment (discretionary investment agreement). Change in material contracts such as collateral agreements
- Heights Capital Management, Inc.: 9.1%→9.0% (2026/02/20) - Pure investment (discretionary investment agreement). Change in material contracts such as collateral agreements
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.

